AI assistant
MYRIAD GENETICS INC — Director's Dealing 2019
Sep 26, 2019
32566_dirs_2019-09-26_3d1a5ae5-b7af-4a84-a792-74c3b745d6f9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: MYRIAD GENETICS INC (MYGN)
CIK: 0000899923
Period of Report: 2019-09-25
Reporting Person: Tobin Bernard (President Crescendo BioScience)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-09-25 | Common Stock | A | 35000 | $0.0 | Acquired | 181040 | Direct |
| 2019-09-25 | Common Stock | D | 4339 | $29.93 | Disposed | 176701 | Direct |
| 2019-09-25 | Common Stock | D | 4958 | $29.93 | Disposed | 171743 | Direct |
Footnotes
F1: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests 25% on September 26, 2020, 25% on September 26, 2021, 25% on September 26, 2022, and 25% on September 26, 2023.
F2: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person.